Info

FIGURE 2 Top panel: Comparison of inhibition of binding of human IgE to the high-affinity FceRI receptor by HAE1 and omalizumab. The absorbance at A450 nm-A620 nm was a measure of biotin IgE binding to FceRI. The IC50 values for inhibition of biotin IgE binding to FceRI were 2.69 and 0.053 mg/mL for omalizumab and HAE1, respectively. Bottom panel: Comparison of suppression of free IgE in humans after administration of a single subcutaneous dose of HAE1 at 90 mg or omalizumab at 150 mg. Abbreviations: Ig, immunoglobulin; FceR, fragment crystallizable e receptor. Source: Figure prepared by Wendy Putnam (Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc.) and Don Sinclair (Clinical PK/PD-Biotherapeutics Department, Genentech, Inc.).

FIGURE 2 Top panel: Comparison of inhibition of binding of human IgE to the high-affinity FceRI receptor by HAE1 and omalizumab. The absorbance at A450 nm-A620 nm was a measure of biotin IgE binding to FceRI. The IC50 values for inhibition of biotin IgE binding to FceRI were 2.69 and 0.053 mg/mL for omalizumab and HAE1, respectively. Bottom panel: Comparison of suppression of free IgE in humans after administration of a single subcutaneous dose of HAE1 at 90 mg or omalizumab at 150 mg. Abbreviations: Ig, immunoglobulin; FceR, fragment crystallizable e receptor. Source: Figure prepared by Wendy Putnam (Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc.) and Don Sinclair (Clinical PK/PD-Biotherapeutics Department, Genentech, Inc.).

levels (>700 IU/mL) and (ii) improved dosing convenience. Although many asthma patients treated with omalizumab require multiple, biweekly subcutaneous injections, a higher-affinity molecule might require a lower dose and/or less frequent dosing regimen. As Figure 2 lower panel shows, a 90-mg dose of HAE1 achieved greater suppression of free IgE in humans than omalizumab at a 150-mg dose. This data must be interpreted with caution given that the free IgE levels were measured using different assays, and the two anti-IgE molecules were evaluated in different studies. However, the results strongly suggest that the higher affinity and the increased in vitro potency of HAE1 did translate into greater in vivo potency.

Coping with Asthma

Coping with Asthma

If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.

Get My Free Ebook


Post a comment